To deeply implement Jilin Province's strategy for promoting high-quality development of the pharmaceutical and healthcare industry, and actively respond to the province’s industrial spatial layout under the "One Main, Six Duals" initiative for building a pharmaceutical and healthcare industry corridor, the province aims to transform the pharmaceutical and healthcare sector—from a traditional strength—into a new pillar industry that will receive key support during the 13th Five-Year Plan period and beyond. On the afternoon of July 13, Xu Hui, Vice Mayor of Liaoyuan City, along with his delegation, visited our company’s Changchun Institute of Pharmaceutical Research to explore and assess potential opportunities for establishing a new R&D platform focused on chemical drugs in Liaoyuan City. Accompanying the delegation were Chairman Duan Chengjun, General Manager Xie Wenbo, and other senior company leaders who joined the inspection and discussion. The vice mayor and his team toured the company’s flagship products, cutting-edge R&D instruments and equipment, as well as specialized scientific research tools, gaining valuable insights into the company’s product development processes and innovations. Following the tour, the delegation held a cordial meeting with the company’s leadership. During the meeting, Chairman Duan and General Manager Xie warmly welcomed Vice Mayor Xu and provided an overview of the company’s growth trajectory, highlighting its robust R&D capabilities, advanced production technologies, and clear strategic direction. They also emphasized: First, the company remains steadfastly committed to R&D as its technological cornerstone, continuously building a comprehensive R&D value chain; Second, the company boasts a highly skilled R&D team with extensive project development expertise and multiple mature technology platforms, enabling it to collaborate effectively with numerous pharmaceutical companies, clinical research institutions, and academic partners; Third, they expressed their aspiration for the company to play an active role in bolstering Liaoyuan City’s pharmaceutical industry development. Vice Mayor Xu commended Bo Da Wei Ye on its remarkable achievements over recent years, engaging in in-depth discussions about potential collaborative initiatives. He also shared invaluable insights aimed at supporting the company’s continued growth and expansion.

On September 9, 2020, Wang Shaobo and Jiang Kuihong, Vice Presidents of the Municipal Party School, led a delegation of nine members to our company for a research visit. They were accompanied by Duan Chengjun, Chairman, and Wu Shaohui, Deputy General Manager. During the visit, Chairman Duan provided the delegation with a detailed overview of the company’s development journey, including its production operations, R&D innovations, non-public sector party building initiatives, future growth prospects, and insightful visions for the long-term development of Liaoyuan's pharmaceutical industry—often responding thoughtfully to questions raised by the team. The research group expressed deep admiration for our company’s remarkable achievements over the past decade, as well as its longstanding commitment to public health and improving people’s livelihoods. They particularly praised Chairman Duan’s initiative in establishing the Pharmaceutical Industry Alliance and the Pharmaceutical Health Industry Chamber of Commerce, which have played a pivotal role in boosting Liaoyuan’s pharmaceutical sector. This "down-to-earth" visit and research session effectively bridged classroom theory with real-world practice, enabling us to refine our teaching approaches, innovate training methods, and further enhance the teaching and research capabilities of our faculty and staff. The delegation concluded by extending their best wishes to Bodaweiyey for continued success in its noble mission of advancing human health. They also pledged to strengthen their focus on and support for local enterprises, leveraging their extensive network and collaborative expertise to actively contribute to the economic growth and prosperity of our city.

Braving the sweltering heat of 35 degrees Celsius and battling the relentless heat waves, on the afternoon of July 23, a delegation of more than 10 members—including Mu Kezhen, Deputy Director of the Provincial Department of Industry and Information Technology; Ma Guang, Director of the Consumer Goods Division of the same department; and Zhang Yinghong, Director of the Pharmaceutical Division—visited our company to inspect and assess our production operations. Executive Vice President Wu Shaohui provided the visiting team with a detailed overview of our company’s development journey and current operational status, patiently answering their questions along the way. The delegation expressed admiration for our company’s steadfast commitment to advancing human health over the past decade, particularly in the fields of biochemical pharmaceuticals, with a strong focus on research, development, manufacturing, and sales of drugs targeting cardiovascular and cerebrovascular diseases, digestive disorders, cancer treatments, and neuropsychiatric conditions. Deputy Director Mu Kezhen emphasized the need to overcome the adverse effects of the pandemic, maintain unwavering confidence in growth, and accurately monitor emerging trends and developments within the industry. He urged companies to continuously strengthen technological upgrades and innovation efforts, thereby enhancing their core competitiveness. Meanwhile, all departments under the Provincial Department of Industry and Information Technology pledged to bolster their service mindset, proactively offering support by stepping up assistance in areas such as policies, technology, financing, and talent acquisition. These measures aim to create an optimal environment for enterprise growth, accelerate the implementation of supportive policies, and ensure the healthy and rapid development of businesses.

On August 12, during the height of summer, the Provincial Drug Administration held a symposium at our company to support the development of enterprises specializing in "two products and one medical device." Attendees included Wang Hong and Lan Wengchi, Deputy Directors of the Provincial Drug Administration; relevant officials from the Provincial Drug Administration's Departments of Pharmaceutical Distribution, Medical Device Management, and Production Supervision; Vice Mayor Xu Hui; and over 40 representatives from 15 pharmaceutical manufacturers, 3 medical device producers, and two pharmaceutical wholesale-retail chain headquarters based in our city. General Manager Xie Wenbo took the lead in briefing the attending leaders on our company's development progress. He then raised five key issues—namely, the market launch and sales of active pharmaceutical ingredients, batch changes in production lines, filing procedures, reporting protocols, and the renewal of the "Production License"—seeking guidance from the officials present. After carefully listening to reports from multiple pharmaceutical and medical device companies, the provincial drug administration officials provided detailed policy clarifications right on the spot. Vice Mayor Xu Hui delivered a speech, expressing gratitude to the provincial drug administration officials for braving the sweltering heat to conduct on-site consultations and address enterprises' concerns, particularly highlighting their extensive efforts during the COVID-19 pandemic. He emphasized that, under the guidance of the provincial bureau, the Liaoyuan Branch should actively contribute to the healthy growth of Liaoyuan's pharmaceutical industry. Additionally, he urged all pharmaceutical and medical device companies to promptly review and thoroughly implement the requirements, solutions, and measures proposed by the research team, always prioritizing the safety and quality of medicines above all else. By doing so, they can continuously enhance product quality and safety standards, ensuring that the public has access to reliable, high-quality medications.

On August 20, a development seminar of the Jilin Province Chemical Pharmaceutical Industry Technology Innovation Strategic Alliance was held at Bodaweiye Pharmaceutical Co., Ltd., hosted by the Jilin Province Modern Traditional Chinese Medicine and Biopharmaceutical Base Construction Office and organized by Bodaweiye Pharmaceutical Co., Ltd. The event aimed to deepen the alliance's initiatives, foster the healthy growth of Jilin's chemical pharmaceutical industry, and drive technological innovation within the sector. Attending the meeting were representatives from the Jilin Provincial Department of Science and Technology, the Liaoyuan Municipal Bureau of Science and Technology, and the Management Committee of Liaoyuan Economic Development Zone. Additionally present were key leaders from Bodaweiye Pharmaceutical Co., Ltd., the chairman of the alliance’s board of directors, Duan Chengjun; the company’s general manager, Xie Wenbo; as well as executives from other alliance member companies, including Xue Chuanxiao, Chairman of Shihuida Pharmaceutical Group Co., Ltd., and Zhang Jun, Chairman of Xidian Pharmaceutical Technology Development Co., Ltd. Also in attendance were nearly 30 participants, including Li Hao, Dean of the School of Pharmacy at Yanbian University, along with representatives from four leading universities and research institutions. During the seminar, Duan Chengjun, Chairman of Bodaweiye Pharmaceutical Co., Ltd., and other pharmaceutical company leaders delivered keynote speeches. Attendees then engaged in discussions centered on the alliance’s operational mechanisms, management models, and priority tasks. Topics included technical needs and collaborative projects among members related to chemical drug R&D, pilot-scale testing, and production, as well as strategies for joint applications by alliance members to the 2016 Jilin Provincial Science and Technology Development Plan projects. Participants also shared ideas aimed at further clarifying the alliance’s strengths, strengthening collaboration, and leveraging complementary advantages, ultimately outlining specific goals and responsibilities for the alliance’s future activities. The meeting concluded with the adoption of a rotating chairmanship system, designating Xue Chuanxiao, Chairman of Shihuida Pharmaceutical Group Co., Ltd., as the 2016 rotating chairperson. Additionally, a specialized Technical Expert Committee was established, with Su Li, Director of the Jilin Provincial Institute of Pharmaceutical Research, appointed as its chairperson. Finally, a permanent secretariat was set up, and Liu Daocheng, Secretary-General of the Jilin Provincial Pharmaceutical Industry Association, was appointed as the alliance’s executive secretary-general. This meeting marked a significant step forward in fully advancing the work of the Jilin Province Chemical Pharmaceutical Industry Technology Innovation Strategic Alliance, ensuring that its operations move toward greater scientific rigor, regularity, and institutionalization. It also enhanced the proactive engagement and enthusiasm of alliance members, fostering a mutually beneficial, interconnected, and highly efficient operating framework. Ultimately, these developments signify that the Jilin Province Chemical Pharmaceutical Innovation Strategic Alliance has entered a new phase of growth and maturity.